Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Eduardo Ríos Herranz"'
Autor:
Pau Abrisqueta, Eva González-Barca, Christelle Ferrà, Eduardo Ríos-Herranz, Margarita Fernández de la Mata, Julio Delgado, Rafael Andreu, José Ángel Hernández-Rivas, María José Terol, Almudena Navarro, M. Belén Vidriales, Patricia Baltasar, Javier De la Serna, Ángel Ramírez, Carmen Ballester, Carol Moreno, José Antonio García-Marco, Raúl Córdoba, Lucrecia Yáñez, Luís Felipe Casado, Marcos González, Francesc Bosch
Publikováno v:
EClinicalMedicine, Vol 73, Iss , Pp 102642- (2024)
Summary: Background: BTK inhibitors have been concurrently administered with anti-CD20 monoclonal antibodies (mAbs) in chronic lymphocytic leukemia (CLL). However, the optimal regimen for combining these two drugs remains pending. Methods: This multi
Externí odkaz:
https://doaj.org/article/0409832eb56e42f09c46046064da1b29
Autor:
Lourdes Hontecillas-Prieto, Daniel J. García-Domínguez, Natalia Palazón-Carrión, Alejandro Martín García-Sancho, Esteban Nogales-Fernández, Carlos Jiménez-Cortegana, María L. Sánchez-León, Silvia Silva-Romeiro, Rocío Flores-Campos, Fernando Carnicero-González, Eduardo Ríos-Herranz, Fátima de la Cruz-Vicente, Guillermo Rodríguez-García, Rubén Fernández-Álvarez, Natividad Martínez-Banaclocha, Josep Gumà-Padrò, José Gómez-Codina, Antonio Salar-Silvestre, Delvys Rodríguez-Abreu, Laura Gálvez-Carvajal, Jorge Labrador, María Guirado-Risueño, Mariano Provencio-Pulla, Margarita Sánchez-Beato, Lejeune Marylene, Tomás Álvaro-Naranjo, María Casanova-Espinosa, Antonio Rueda-Domínguez, Víctor Sánchez-Margalet, Luis de la Cruz-Merino
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundDiffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma worldwide. DLBCL is an aggressive disease that can be cured with upfront standard chemoimmunotherapy schedules. However, in approximately 35-40% of the patients D
Externí odkaz:
https://doaj.org/article/212d6baeaf2d4c8bb7bf0ab05ba40793
Autor:
Mariano Provencio, Luis de la Cruz-Merino, Delvys Rodriguez-Abreu, Tomás Álvaro, Marylène Lejeune, Carlos Jiménez-Cortegana, Natalia Palazón-Carrión, Alejandro Martin Garcia-Sancho, Esteban Nogales-Fernandez, Fernando Carnicero-González, Eduardo Ríos-Herranz, Fatima de la Cruz-Vicente, Guillermo Rodríguez-García, Rubén Fernández-Álvarez, Antonio Rueda Dominguez, Maria Casanova-Espinosa, Natividad Martínez-Banaclocha, Josep Gumà-Padrò, José Gómez-Codina, Jorge Labrador, Antonio Salar-Silvestre, Laura Galvez-Carvajal, Margarita Sánchez-Beato, María Guirado-Risueño, Pablo Espejo-García, Victor Sánchez-Margalet
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
Background The search for immunological markers with ability of predicting clinical outcome is a priority in lymphomas, and in cancer in general. It is well known that some immunomodulatory cells, such as myeloid derived suppressor cells (MDSCs) or r
Externí odkaz:
https://doaj.org/article/b89f60e62bf043c59fe379aa70ec66e3
Autor:
Luis de la Cruz-Merino, Antonio Rueda-Domínguez, Victor Sánchez-Margalet, Maria Casanova-Espinosa, Tomás Álvaro-Naranjo, Lejeune Marylene, Marta Navarro, Margarita Sánchez-Beato, Mariano Provencio-Pulla, Isabel Fernández-Román, Pablo Espejo-García, Lourdes Hontecillas-Prieto, Daniel J. García-Domínguez, María Guirado-Risueño, Jorge Labrador, Laura Gálvez-Carvajal, Delvys Rodríguez-Abreu, Antonio Salar-Silvestre, José Gómez-Codina, Josep Gumà-Padrò, Natividad Martínez-Banaclocha, Rubén Fernández-Álvarez, Guillermo Rodríguez-García, Fátima de la Cruz-Vicente, Eduardo Ríos-Herranz, Fernando Carnicero-González, Carlos Jiménez-Cortegana, Esteban Nogales-Fernández, Alejandro Martín García-Sancho, Natalia Palazón-Carrión
Supplementary Table from Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bf9183a00b8270cb46c8800a40d5d32
https://doi.org/10.1158/1078-0432.22487339
https://doi.org/10.1158/1078-0432.22487339
Autor:
Luis de la Cruz-Merino, Antonio Rueda-Domínguez, Victor Sánchez-Margalet, Maria Casanova-Espinosa, Tomás Álvaro-Naranjo, Lejeune Marylene, Marta Navarro, Margarita Sánchez-Beato, Mariano Provencio-Pulla, Isabel Fernández-Román, Pablo Espejo-García, Lourdes Hontecillas-Prieto, Daniel J. García-Domínguez, María Guirado-Risueño, Jorge Labrador, Laura Gálvez-Carvajal, Delvys Rodríguez-Abreu, Antonio Salar-Silvestre, José Gómez-Codina, Josep Gumà-Padrò, Natividad Martínez-Banaclocha, Rubén Fernández-Álvarez, Guillermo Rodríguez-García, Fátima de la Cruz-Vicente, Eduardo Ríos-Herranz, Fernando Carnicero-González, Carlos Jiménez-Cortegana, Esteban Nogales-Fernández, Alejandro Martín García-Sancho, Natalia Palazón-Carrión
Purpose:New therapeutic options are needed in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Lenalidomide-based schedules can reverse rituximab refractoriness in lymphoma.Patients and Methods:In the phase II R2-GDP trial, 78 patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3f3c37b5b07b0c28088ac4cb012473f
https://doi.org/10.1158/1078-0432.c.6532499
https://doi.org/10.1158/1078-0432.c.6532499
Autor:
Luis de la Cruz-Merino, Antonio Rueda-Domínguez, Victor Sánchez-Margalet, Maria Casanova-Espinosa, Tomás Álvaro-Naranjo, Lejeune Marylene, Marta Navarro, Margarita Sánchez-Beato, Mariano Provencio-Pulla, Isabel Fernández-Román, Pablo Espejo-García, Lourdes Hontecillas-Prieto, Daniel J. García-Domínguez, María Guirado-Risueño, Jorge Labrador, Laura Gálvez-Carvajal, Delvys Rodríguez-Abreu, Antonio Salar-Silvestre, José Gómez-Codina, Josep Gumà-Padrò, Natividad Martínez-Banaclocha, Rubén Fernández-Álvarez, Guillermo Rodríguez-García, Fátima de la Cruz-Vicente, Eduardo Ríos-Herranz, Fernando Carnicero-González, Carlos Jiménez-Cortegana, Esteban Nogales-Fernández, Alejandro Martín García-Sancho, Natalia Palazón-Carrión
Supplementary Data from Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e5587b44b63c51aeac3b6410ed474a9
https://doi.org/10.1158/1078-0432.22487342
https://doi.org/10.1158/1078-0432.22487342
Autor:
Rocío Díaz Acedo, Silvia Artacho Criado, Eduardo Ríos Herranz, Antonio Gutiérrez Pizarraya, Irene Sánchez Romero, Esther Márquez Saavedra
Publikováno v:
Journal of Oncology Pharmacy Practice. :107815522311625
Introduction Hypogammaglobulinemia after front-line immunochemotherapy for follicular lymphoma is a poorly studied adverse event that could be related to the appearance of severe and/or recurrent non-neutropenic infections which could affect the qual
Autor:
Natalia Palazón-Carrión, Alejandro Martín García-Sancho, Esteban Nogales-Fernández, Carlos Jiménez-Cortegana, Fernando Carnicero-González, Eduardo Ríos-Herranz, Fátima de la Cruz-Vicente, Guillermo Rodríguez-García, Rubén Fernández-Álvarez, Natividad Martínez-Banaclocha, Josep Gumà-Padrò, José Gómez-Codina, Antonio Salar-Silvestre, Delvys Rodríguez-Abreu, Laura Gálvez-Carvajal, Jorge Labrador, María Guirado-Risueño, Daniel J. García-Domínguez, Lourdes Hontecillas-Prieto, Pablo Espejo-García, Isabel Fernández-Román, Mariano Provencio-Pulla, Margarita Sánchez-Beato, Marta Navarro, Lejeune Marylene, Tomás Álvaro-Naranjo, Maria Casanova-Espinosa, Victor Sánchez-Margalet, Antonio Rueda-Domínguez, Luis de la Cruz-Merino
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
CLINICAL CANCER RESEARCH
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
CLINICAL CANCER RESEARCH
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
Purpose: New therapeutic options are needed in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Lenalidomide-based schedules can reverse rituximab refractoriness in lymphoma. Patients and Methods: In the phase II R2-GDP trial, 78 patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75a5e119dc106abd893979e1e139f166
http://hdl.handle.net/10230/54477
http://hdl.handle.net/10230/54477
Autor:
Alicia Smucler Simonovich, Eduardo Ríos Herranz, José A. Márquez, Sandra Iraheta, Angel Ramirez Payer, Macarena Ortiz, Javier Loscertales, Ernesto Pérez Persona, Jose Manuel Puerta, María José Terol, Javier de la Serna, Patricia Baltasar, José A. García-Marco, Begoña Muiña, Tomas García, Rafael Andreu, Fatima De la Cruz, Ana Muntañola Prat, Gonzalo Caballero, Diana Moreno, Marcos González Díaz, Ruben Fernandez, Juan Marquet Palomanes, Laura Magnano, Carol Moreno, María Angeles Andreu, Jose M Arguiñano, Ana Ruiz-Zorrilla, Santiago Osorio, Lucrecia Yáñez, Christelle Ferra, Manuel Pérez-Encinas
Publikováno v:
Blood. 138:1561-1561
Introduction: The BCL-2 inhibitor venetoclax (Ven) has been approved on monotherapy or combined with rituximab in relapsed/refractory CLL patients (pts) and combined with obinutuzumab in previously untreated CLL pts. However, evidence from clinical t
Autor:
Pau Abrisqueta, Lucrecia Yáñez San Segundo, Carmen Ballester, Patricia Baltasar Tello, Eduardo Ríos Herranz, Raul Cordoba, Marcos González, Javier de la Serna, María José Terol, Rafael Andreu, Margarita Fernandez, Eva González-Barca, José A. García-Marco, Angel Ramirez Payer, Jose Angel Hernandez-Rivas, Francesc Bosch, Carol Moreno, Christelle Ferra, Luis Felipe Casado Montero, Julio Delgado
Publikováno v:
Blood
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Introduction. Despite the high proportion of prolonged remissions obtained with ibrutinib in patients with CLL, complete responses (CR) are rarely observed. For the purpose of increasing the deepness of response, ibrutinib has been tested in combinat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a028b7338e2787fe90325ae813fd7f6
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4278
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4278